On June 4, 2019, SANUWAVE Health, Inc., a Nevada corporation (the “Company”), entered into an agreement (the “Deed of Termination of Joint Venture Agreement”) with Johnfk Medical Inc. (“FKS”) andHolistic Wellness Alliance Pte. Ltd. (“HWA”), effective as of June 4, 2019. to the Deed of Termination of Joint Venture Agreement (the “JV Agreement”), the Company and FKS terminated the Joint Venture Agreement, dated as of September 21, 2018, that established HWA as a joint venture between the Company and FKS.

to the Deed of Termination of Joint Venture Agreement, FKS will pay the Company the outstanding amount of $63,275 for equipment delivered to FKS and a penalty fee of $50,000 for early termination of the JV Agreement. The Company and FKS desire to provide for the liquidation of HWA as soon as reasonably practicable.

The foregoing description of the Deed of Termination of Joint Venture Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Deed of Termination of Joint Venture Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

SANUWAVE Health, Inc. Exhibit
EX-10.1 2 snwv_ex101.htm AGREEMENT TERMINATION Blueprint   Exhibit 10.1   DEED OF TERMINATION OF JOINT VENTURE AGREEMENT       This Deed of Termination of Joint Venture Agreement (“Deed”) is made on this 4th day of June 2019 (the “Effective Date”),…
To view the full exhibit click here

About SANUWAVE HEALTH, INC. (OTCMKTS:SNWV)

SANUWAVE Health, Inc. is an acoustic pressure shock wave technology company using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The Company is focused on regenerative medicine utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, enabling to restore the body’s normal healing processes and regeneration. It is focused on developing its Pulsed Acoustic Cellular Expression (PACE) technology to activate healing in wound conditions.